07:25 AM EDT, 08/28/2024 (MT Newswires) -- GSK (GSK) said Wednesday that Japan's Ministry of Health, Labor and Welfare had approved Nucala, or mepolizumab, to treat chronic rhinosinusitis with nasal polyps in adults.

The approval is based on phase 3 trial data and supported by the results of a global study, GSK said.

Mepolizumab is also approved in Japan for bronchial asthma in children aged 6 and older and for refractory asthma and eosinophilic granulomatosis with polyangiitis in adults, GSK added.

Price: 43.50, Change: -0.65, Percent Change: -1.47